azane; 2-methylpyridine; platinum(2+); dichloride
3D model (Jmol)
|Molar mass||376.14 g·mol−1|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|what is ?)(|
In Phase I and Phase II clinical trials, picoplatin demonstrated activity in a variety of solid tumors, including lung, ovarian, colorectal and hormone-refractory prostate cancer. However, in Phase III trials, picoplatin failed to hit its primary endpoint for advanced small cell lung cancer. Hopes are now pinned on its use for metastatic colorectal cancer.
- The status of platinum anticancer drugs in the clinic and in clinical trials Dalton Transactions
- Picoplatin Clinical Results, Poniard Pharmaceuticals
- Poniard shares crash on Phase III picoplatin failure, fiercebiotech.com, November 16, 2009
- http://www.genengnews.com/specialreports/sritem.aspx?oid=69418732 Nov 2009
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|